MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

Search

Bayer AG

Avatud

SektorRahandus

21.44 -5.15

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.16

Max

22.575

Põhinäitajad

By Trading Economics

Sissetulek

3.9B

-328M

Müük

1.8B

12B

P/E

Sektori keskmine

30.9

22.015

Aktsiakasum

1.05

Dividenditootlus

0.49

Kasumimarginaal

-2.796

Töötajad

90,587

EBITDA

615M

1.7B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+20.47% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.49%

3.90%

Turustatistika

By TradingEconomics

Turukapital

422M

22B

Eelmine avamishind

26.59

Eelmine sulgemishind

21.44

Uudiste sentiment

By Acuity

31%

69%

96 / 542 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Bayer AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. märts 2025, 09:37 UTC

Suurimad hinnamuutused turgudel

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5. märts 2025, 11:21 UTC

Tulu

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5. märts 2025, 08:45 UTC

Tulu

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5. märts 2025, 07:26 UTC

Tulu

Bayer Warns of Lower Earnings as Work Continues on Turnaround

10. märts 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

5. märts 2025, 13:39 UTC

Market Talk
Tulu

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5. märts 2025, 13:26 UTC

Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5. märts 2025, 08:30 UTC

Market Talk
Tulu

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5. märts 2025, 06:41 UTC

Tulu

Bayer Launches Plan to Boost Profitability at Crop Science

5. märts 2025, 06:40 UTC

Tulu

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5. märts 2025, 06:39 UTC

Tulu

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5. märts 2025, 06:39 UTC

Tulu

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5. märts 2025, 06:36 UTC

Tulu

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5. märts 2025, 06:35 UTC

Tulu

Bayer Guidance is on a Currency Adjusted Basis

5. märts 2025, 06:34 UTC

Tulu

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5. märts 2025, 06:34 UTC

Tulu

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5. märts 2025, 06:33 UTC

Tulu

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5. märts 2025, 06:33 UTC

Tulu

Bayer Sees 2025 Sales EUR45B-EUR47B

5. märts 2025, 06:32 UTC

Tulu

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5. märts 2025, 06:31 UTC

Tulu

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5. märts 2025, 06:31 UTC

Tulu

Bayer 4Q Net Loss EUR335M

5. märts 2025, 06:31 UTC

Tulu

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5. märts 2025, 06:31 UTC

Tulu

Bayer 4Q Ebitda Before Special Items EUR2.35B

5. märts 2025, 06:31 UTC

Tulu

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5. märts 2025, 06:31 UTC

Tulu

Bayer 4Q Sales EUR11.73B

13. jaan 2025, 21:05 UTC

Peamised uudised

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9. jaan 2025, 15:06 UTC

Omandamised, ülevõtmised, äriostud

Bayer Didn't Disclose Financial Details

9. jaan 2025, 15:05 UTC

Omandamised, ülevõtmised, äriostud

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9. jaan 2025, 15:05 UTC

Omandamised, ülevõtmised, äriostud

Bayer: Camelina Is Novel Intermediate Oilseed Crop

9. jaan 2025, 15:04 UTC

Omandamised, ülevõtmised, äriostud

Bayer: Smart Earth Camelina Is Headquartered in Saskatoon, Saskatchewan, Canada

Võrdlus sarnastega

Hinnamuutus

Bayer AG Prognoos

Hinnasiht

By TipRanks

20.47% tõus

12 kuu keskmine prognoos

Keskmine 26.89 EUR  20.47%

Kõrge 33 EUR

Madal 22 EUR

Põhineb 10 Wall Streeti analüütiku instrumendi Bayer AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

10 ratings

1

Osta

9

Hoia

0

Müü

Tehniline skoor

By Trading Central

21.95 / 22.575Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

96 / 542 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.